Loading
Diabetes Treatment and Management · Journal article
American Journal of Physiology-endocrinology and Metabolism · September 3, 2026
Raises a question worth testing. It does not answer one.
This preclinical study demonstrates that metformin and bariatric surgery (RYGB or SG) each independently improve glucose tolerance and insulin sensitivity in non-obese diabetic rats, with additive effects on postprandial glycemic control when combined. The work is mechanistic exploration in an animal model with limited direct translational relevance to human clinical decision-making; the authors themselves call for longer-term, sex-inclusive studies to enhance translational validity.
Controlled preclinical animal experiment. Female Goto-Kakizaki (GK) rats, a non-obese insulin-deficient model of type 2 diabetes. Intervention: Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG), with or without metformin 50 mg/kg/day. Compared with: Sham surgery with or without metformin; vehicle control.
RYGB and SG reduced body weight, food intake, leptin levels, and improved fasting glucose and glucose tolerance Metformin alone improved glucose tolerance and insulin sensitivity independently of incretin or insulin changes Metformin combined with surgery further reduced postprandial glycemic excursions but did not enhance insulin sensitivity or hormone secretion beyond surgery alone
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Preclinical animal study in a non-obese diabetic rat model that raises mechanistic questions about metformin and bariatric surgery combination; not designed to inform human clinical practice.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This study investigates the individual and combined effects of Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), and metformin on glucose regulation in a non-obese, insulin-deficient model of type 2 diabetes. Female Goto-Kakizaki (GK) rats underwent RYGB, SG, or sham surgery. Three weeks postoperatively, animals received metformin (50 mg/kg/day, 5 days/week) or vehicle for three additional weeks. Glucose tolerance was assessed using a standardized meal test, and insulin sensitivity was evaluated by insulin tolerance test. Plasma levels of GLP-1, GIP, insulin, and leptin were measured. RYGB and SG reduced body weight, food intake, and leptin levels, and improved fasting glucose, glucose tolerance, insulin sensitivity, and postprandial incretin and insulin secretion. Metformin alone improved glucose tolerance and insulin sensitivity independently of incretin or insulin changes. When combined with surgery, metformin further reduced postprandial glycemic excursions but did not enhance insulin sensitivity or hormone secretion beyond surgery alone. In conclusion, metabolic-bariatric surgery and metformin independently improve glucose regulation in non-obese diabetic GK rats. Their combination provides additional benefits on postprandial glucose control, despite no additional effects on insulin sensitivity or hormone levels. These findings support the use of metformin as an adjunct to metabolic-bariatric surgery in insulin-deficient diabetes and highlight the need for longer-term, sex-inclusive studies to enhance translational relevance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.